US2007065451A1PendingUtilityA1

Enhancement of intracellular delivery and tissue targeting of drugs and genes

Individually held — no corporate assignee on recordPriority: Mar 10, 1998Filed: Nov 15, 2006Published: Mar 22, 2007
Est. expiryMar 10, 2018(expired)· nominal 20-yr term from priority
A61P 43/00C07K 2317/77A61P 37/02A61K 47/6898C07K 16/2803B82Y 5/00
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for enhancing intracellular delivery of effector molecules is provided. The method involves modifying selected antibodies with biotin and streptavidin, conjugating these antibodies with an effector molecule, and delivering the conjugated effector to an intracellular target specifically recognized by the antibody.

Claims

exact text as granted — not AI-modified
1 . A method of increasing cellular internalization or accumulation of a poorly internalized antibody in a target cell, said method comprising: 
 (a) biotinylating a poorly internalized antibody recognizing a specific antigen on a surface of a target cell, said poorly internalized antibody exhibiting cellular internalization of less than 20% in the target cell; and    (b) conjugating the biotinylated antibody of step (a) with streptavidin to produce a streptavidin-biotinylated antibody conjugate, wherein cellular internalization or accumulation of said streptavidin-biotinylated antibody conjugate in the target cell is increased as compared to cellular internalization or accumulation of said poorly internalized antibody.    
     
     
         2 . A method for intracellularly delivering an effector to a target cell of an animal comprising: 
 (a) biotinylating a poorly internalized antibody recognizing a specific antigen on a surface of a target cell, said poorly internalized antibody exhibiting cellular internalization of less than 20% in the target cell;    (b) conjugating the biotinylated antibody with streptavidin to form a streptavidin-biotinylated antibody carrier;    (c) conjugating said streptavidin-biotinylated antibody carrier with an effector; and    (d) administering the streptavidin-biotinylated antibody carrier-effector conjugate to an animal so that the effector of the conjugate formed in step (c) is delivered intracellularly to the target cell.    
     
     
         3 . The method of  claim 2  wherein the effector produces oxidative injury in the target cells when delivered intracellularly thereby killing the target cells.

Join the waitlist — get patent alerts

Track US2007065451A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.